Sign In
Buy IVA
$3.71
+0.200 (+5.70%)
At Close: Jun 23, 2026
Claret Capital Partners participates in €130m financing for Inventiva
05:12am, Tuesday, 16'th Jun 2026
Claret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASH Claret Capital Pa
Claret Capital Partners participates in €130m financing for Inventiva
05:12am, Tuesday, 16'th Jun 2026
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing, to support its lead asset through Phase 3.
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
04:52am, Tuesday, 16'th Jun 2026
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing, to support its lead asset through Phase 3.
Daix (France), New York City (New York, United States), June 12, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround
10:36am, Thursday, 11'th Jun 2026
The heavy selling pressure might have exhausted for Inventiva (IVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i
Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
04:00pm, Tuesday, 09'th Jun 2026
Daix (France), New York City (New York, United States), June 9,2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company fo
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
08:30am, Tuesday, 02'nd Jun 2026
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company f
Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
01:30am, Tuesday, 02'nd Jun 2026
Daix (France), New York City (New York, United States), le 2 juin 2026 - Inventiva (Euronext Paris et NASDAQ: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée da
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
01:30am, Tuesday, 02'nd Jun 2026
Daix (France), New York City (New York, United States), June 2, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on
Inventiva Reports 2026 First Quarter Financial Information¹
04:00pm, Tuesday, 26'th May 2026
Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company f
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
04:00pm, Thursday, 21'st May 2026
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the
Inventiva's Speculative Upside Through MASH Is Promising
06:22pm, Friday, 15'th May 2026
Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV3 readout, which we should get by Q4 2026. In my view, lanifibranor seems relatively differentiated
Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026
02:30am, Wednesday, 13'th May 2026
Daix (France), New York City (New York, Etats-Unis), le 13 mai 2026 - Inventiva (Euronext Paris et NASDAQ: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique au stade clinique s
Inventiva to Present Abstracts at the EASL Congress 2026
02:30am, Wednesday, 13'th May 2026
Daix (France), New York City (New York, United States) , May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compa
